GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
1k
c/trialwatch·posted 2 years ago by u/yusuf_ramos

SURPASS — 22 things I got wrong before I got it right

Readout Clean Column ×8 Sourced ×1

SURPASS — 22 things I got wrong before I got it right. Not a hot take, just something I have not seen said plainly here.

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.

1,346 up / 304 down82% upvoted37 commentsid 58cezo23 Jul 2024

37 comments

8 in this archive, depth 4

best — the order this archive was captured in

u/ines_boateng148 points·2 years ago

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

replysharereportpermalink
u/sofia_wikstrom117 points·2 years ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink
u/joaquin_stanescu66 points·2 years ago

How long was the randomised phase before any extension?

replysharereportpermalink
u/yusuf_ramosOP51 points·2 years ago

Do you have the publication or the press release?

replysharereportpermalink
u/nikhil_lindqvist60 points·2 years ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/trialwatch_theoMOD31 points·2 years ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/nikhil_lindqvist9 points·2 years ago

open-label extensions are not the same evidence as the randomised phase

replysharereportpermalink
u/adaeze_weiss4 points·2 years ago

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

replysharereportpermalink
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →